Medline stock is a little too expensive to buy post IPO, Jim Cramer says
- Posted on December 17, 2025
- By CNBC
- 4 Views
Medline stock is a little too expensive to buy post IPO, Jim Cramer says
CNBC's Jim Cramer reviewed Medline, a medical supplies giant that made its market debut Wednesday.
